Cargando…
Postmarketing safety surveillance of dexamethasone intravitreal implant in the treatment of visual impairment due to diabetic macular edema in India
BACKGROUND: Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. As India has the second largest population of diabetic patients worldwide, availability of various treatment options for DME is essential. This postmarketing surveillance study was conducted to ful...
Autores principales: | Nair, Unnikrishnan, Gupta, Vishali, Sharma, Mohita, Joshi, Shrinivas, Sudhalkar, Aditya, Altangerel, Undraa, Bai, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545916/ https://www.ncbi.nlm.nih.gov/pubmed/33036583 http://dx.doi.org/10.1186/s12886-020-01630-7 |
Ejemplares similares
-
Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel, Pravin U, et al.
Publicado: (2015) -
Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema
por: Altintas, Ayse Gul Kocak, et al.
Publicado: (2019) -
Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex(®) in patients with uveitic cystoid macular edema
por: Bansal, Pooja, et al.
Publicado: (2015) -
Bilateral Intravitreal Dexamethasone Implant for Retinitis Pigmentosa-Related Macular Edema
por: Saatci, Ali Osman, et al.
Publicado: (2013) -
Repeated Treatment for Macular Edema in Vein Occlusion by Intravitreal Implant of Dexamethasone
por: Matonti, Frederic, et al.
Publicado: (2012)